Tessera Therapeutics is cutting 90 employees across multiple states. The gene editing company has been reducing its footprint as it focuses resources on its most promising pipeline candidates. At 250 employees pre-layoff, this 36% reduction leaves the company at a fraction of its peak size.
The biotech sector's 2026 corrections are particularly painful because these companies often represent years of scientific research that may never reach patients. Each layoff at a company like Tessera represents not just a lost job but potentially a lost scientific program.